In today's interconnected world, infectious diseases pose an escalating threat, as demonstrated by the coronavirus pandemic ...

Low vaccination rates for influenza viruses and the lack of an HSV vaccine underscore the need for a new approach to reduce viral transmission. Researchers have now used a clinical-grade antiviral ...

This development comes at a time when pharmaceutical firms are discontinuing discovery efforts in next-generation COVID-19 ...

Rutgers Health researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations of Paxlovid, currently the most prescribed oral treatment.

Given the risks to human health, the scientists used a mouse model to test how each antiviral drug worked against the virus when it was obtained through three different exposure routes.

Four antiviral drugs are available for the prevention and treatment of influenza infections: oseltamivir, zanamivir, rimantadine and amantadine. Oseltamivir and zanamivir are neuraminidase ...

Clinical trials moved quickly, and by the end of the year we had the very first oral COVID antiviral, called nirmatrelvir. The pace of the drug’s development was astonishing. Despite using the ...

FINAL TOLL By the time Duterte left office in 2022, the drug war's official toll had at least tripled. Police said 6,200 suspects were killed during anti-drug operations. The Philippine government ...

An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on the horizon. Pfizer—the maker of Paxlovid—has begun Phase 3 ...